European Heart Journal: Cardiovascular Imaging

Nanox.AI’s HealthCCSng AI Solution Reveals ~60% of Patients in Study had Previously Undetected Risk of a Cardiovascular Event from Routine Chest CTs

Retrieved on: 
Thursday, September 28, 2023

NEVE ILAN, Israel, Sept. 28, 2023 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company,” Nasdaq: NNOX), an innovative medical imaging technology company, today announced that HealthCCSng, an AI-powered solution created by Nanox’s deep-learning medical imaging analytics subsidiary, Nanox.AI, was used in a clinical study evaluating routine CT scans and found that 58% of patients unknowingly had moderate to severe levels of coronary artery calcium (CAC), a proven indicator of future cardiac events. The study was sponsored by Nanox.AI and conducted by the Beilinson Hospital, one of the largest and most renowned multidisciplinary medical institutions in Israel, and utilized Nanox.AI’s HealthCCSng, an FDA-cleared and CE marked tool designed specifically for cardiac health assessment.

Key Points: 
  • Nanox.AI’s HealthCCSng solution utilizes medical imaging data from routine chest CT scans to automatically quantify and analyze CAC category.
  • CAC is the strongest predictor of future cardiac events, with patients in the highest category being over 20 times more likely to suffer a cardiac event.
  • “The patients in this study received routine CT scans that had nothing to do with a cardiac concern.
  • HealthCCSng supports clinicians in diagnosing patients with cardiovascular disease who were previously undetected, while stratifying such patients so that they can obtain the appropriate preventative cardiac care and treatment.

FDA Grants Clearance for UltraSight's AI-Powered Cardiac Ultrasound Technology

Retrieved on: 
Thursday, July 27, 2023

TEL AVIV, Israel, July 27, 2023 /PRNewswire/ -- Today, UltraSight, a digital health pioneer transforming cardiac imaging through the power of artificial intelligence, announced that it has been granted FDA clearance for its AI-powered ultrasound guidance technology. The UltraSight real-time AI guidance software can assist medical professionals without sonography experience in acquiring cardiac ultrasound images at the point of care in multiple settings, allowing for more widespread detection of heart disease and providing patients easier access to cardiac monitoring.

Key Points: 
  • TEL AVIV, Israel, July 27, 2023 /PRNewswire/ -- Today, UltraSight , a digital health pioneer transforming cardiac imaging through the power of artificial intelligence, announced that it has been granted FDA clearance for its AI-powered ultrasound guidance technology.
  • In addition, approximately 30 million heart disease patients in the U.S. continue to require periodic cardiac monitoring.
  • However, significant bottlenecks within the U.S. healthcare system, coupled with limited resources for training, restrict access to timely and consistent cardiac ultrasound for patients across the country.
  • UltraSight's software is designed as an accessory for point of care ultrasound systems and is compatible with the Philips Lumify Ultrasound System.

Amarin Highlights New Data Providing Potential Mechanistic Insight into Vascepa®/Vazkepa® (Icosapent Ethyl) Reduction of Cardiovascular Events

Retrieved on: 
Friday, May 12, 2023

DUBLIN, Ireland and BRIDGEWATER, N.J., May 12, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today highlighted new data describing the benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) on coronary physiology, which was published in the European Heart Journal - Cardiovascular Imaging, and plaque progression, which was presented at the American Heart Association’s Vascular Discovery 2023 meeting in Boston, MA, May 10-13.

Key Points: 
  • EVAPORATE demonstrated that in statin-treated patients, VASCEPA/VAZKEPA significantly reduced plaque burden measured by serial coronary computed tomography angiography (CTA) compared with placebo.
  • VASCEPA/VAZKEPA improved mean distal segment FFRCT at 9- and 18-months follow-up compared with placebo (P = 0.02, P = 0.03 respectively).
  • “These new findings from two different studies provide important mechanistic information about VASCEPA/VAZKEPA and further elucidate its value in reducing cardiovascular events in at-risk patients,” said Nabil Abadir, MB.
  • We are proud to add to the body of research that further demonstrates the benefit of VASCEPA/VAZKEPA."

Dr. Scott D. Flamm, Former Section Head of Cardiovascular Imaging at Cleveland Clinic, Joins DocPanel

Retrieved on: 
Monday, May 1, 2023

Formerly with Cleveland Clinic, Dr. Flamm served as Head of Cardiovascular Imaging with joint appointments in the Imaging Institute, Heart, Vascular, and Thoracic Institute, and the Pediatric Institute (2006-2023).

Key Points: 
  • Formerly with Cleveland Clinic, Dr. Flamm served as Head of Cardiovascular Imaging with joint appointments in the Imaging Institute, Heart, Vascular, and Thoracic Institute, and the Pediatric Institute (2006-2023).
  • "DocPanel and I share a mutual mission to make subspecialized cardiac imaging routine care that can be accessed by all," says Dr. Flamm.
  • Through the DocPanel platform, healthcare facilities can access Dr. Flamm for dedicated cardiothoracic imaging coverage, protocol assistance, and program development support.
  • Dr. Flamm completed fellowship training in Cardiovascular Imaging and MRI at the University of California San Francisco under Dr. Charles Higgins.

Live Remote Cardiac MRI Exam to Showcase Vista.ai's Automated and Virtual Scan Capabilities at ACC.23/WCC

Retrieved on: 
Friday, March 3, 2023

NEW ORLEANS, March 3, 2023 /PRNewswire/ -- Vista.ai, a pioneer and leader in automated MRI solutions, today announced that Dr. Michael Salerno, Chief, Cardiovascular Imaging at Stanford Health Care, will conduct a live remote cardiac MRI (CMR) scan using the company's One Click MRI™ software at the American College of Cardiology's 72nd Annual Scientific Session Together With World Heart Federation's World Congress of Cardiology (ACC.23/WCC). Dr. Salerno will scan a patient at Stanford Health in Palo Alto, Calif., virtually from the ACC.23/WCC Future Hub stage in New Orleans at 11 a.m. CST on March 5, 2023.

Key Points: 
  • One Click MRI's benefits include simple, streamlined workflows and improved image consistency, so any MRI technologist can complete a cardiac scan in a regular mixed-use MRI time slot.
  • "With Vista.ai's One Click MRI, CMRs are much more efficient and streamlined, which greatly improves our ability to scan patients who need them.
  • In addition to simplifying clinical workflows and shortening scan times, One Click MRI allows technologists, wherever they are available, to conduct a patient scan at a remote hospital, so long as the facility has an MRI scanner.
  • While One Click MRI is initially focused on automating and simplifying a CMR exam, Vista.ai recently announced planned expansion beyond the heart to other anatomies and clinical areas.

Global Digital Radiology Market Report 2022-2027: Technological Advancements Such as AI-based Digital X-ray Systems Present Opportunities - ResearchAndMarkets.com

Retrieved on: 
Friday, December 16, 2022

The Global Digital Radiology Market is segmented based on Device Type, Product, Applications, End-Users, and Geography.

Key Points: 
  • The Global Digital Radiology Market is segmented based on Device Type, Product, Applications, End-Users, and Geography.
  • By Product, the market is classified into Portable Digital Radiology System and Stationary Digital Radiology System.
  • The report presents a detailed Ansoff matrix analysis for the Global Digital Radiology Market.
  • The report offers a comprehensive evaluation of the Global Digital Radiology Market.

AI Predicts Heart Disease Risk Using Single X-Ray

Retrieved on: 
Tuesday, November 29, 2022

Deep learning is an advanced type of artificial intelligence (AI) that can be trained to search X-ray images to find patterns associated with disease.

Key Points: 
  • Deep learning is an advanced type of artificial intelligence (AI) that can be trained to search X-ray images to find patterns associated with disease.
  • Current guidelines recommend estimating 10-year risk of major adverse cardiovascular disease events to establish who should get a statin for primary prevention.
  • This risk is calculated using the atherosclerotic cardiovascular disease (ASCVD) risk score, a statistical model that considers a host of variables, including age, sex, race, systolic blood pressure, hypertension treatment, smoking, Type 2 diabetes and blood tests.
  • Dr. Weiss and a team of researchers trained a deep learning model using a single chest X-ray (CXR) input.

Radiology Partners Names Dr. Krishna Nallamshetty Chief Medical Officer

Retrieved on: 
Wednesday, June 22, 2022

Radiology Partners (RP), the leading radiology practice in the U.S., announced today that Dr. Krishna Nallamshetty ( @knallamMD ) has been appointed to serve as the practices next Chief Medical Officer (CMO) effective immediately.

Key Points: 
  • Radiology Partners (RP), the leading radiology practice in the U.S., announced today that Dr. Krishna Nallamshetty ( @knallamMD ) has been appointed to serve as the practices next Chief Medical Officer (CMO) effective immediately.
  • RP established its Office of the Chief Medical Officer in 2021.
  • Dr. Nallamshetty is a cardiovascular radiologist and earned his medical degree from Thomas Jefferson University in Philadelphia.
  • Radiology Partners is the largest radiology practice in the U.S., serving more than 3,250 hospitals and other healthcare facilities across the nation.

ASPC Announces a NEW Pre-conference MasterClass on Cardiovascular Imaging Techniques

Retrieved on: 
Thursday, June 2, 2022

The Imaging MasterClass, titled "Imaging Techniques to Assess Global CVD and CVD Risk", is scheduled for July 28-29, 2022, in Louisville, KY. Information on both programs can be found on www.aspconline.org .

Key Points: 
  • The Imaging MasterClass, titled "Imaging Techniques to Assess Global CVD and CVD Risk", is scheduled for July 28-29, 2022, in Louisville, KY. Information on both programs can be found on www.aspconline.org .
  • The Imaging MasterClass will aim to provide simple principles and techniques for various cardiology imaging studies.
  • The Imaging MasterClass will aim to provide simple principles and techniques for various cardiology imaging studies.
  • The ASPC encourages all to join their esteemed faculty to discuss all things related to Cardiovascular Imaging at this brand-new pre-Congress MasterClass.

Neovasc Comments on European Heart Journal Publication

Retrieved on: 
Thursday, April 28, 2022

VANCOUVER and MINNEAPOLIS, April 28, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) today announced that the European Heart Journal has published an article entitled, “Impact of the Coronary Sinus Reducer on Absolute Blood Flow and Microvascular Resistance Case Report.” The article, authored by Francesco Giannini, M.D., Maria Cecilia Hospital, Cotignola, Italy, describes objective improvements in the amount of oxygenated blood delivered to the heart muscle in two patients suffering from refractory angina treated with the Neovasc Reducer™ (“Reducer”).

Key Points: 
  • VANCOUVER and MINNEAPOLIS, April 28, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc , Inc. ("Neovasc" or the "Company") ( NASDAQ , TSX : NVCN) today announced that the European Heart Journal has published an article entitled, Impact of the Coronary Sinus Reducer on Absolute Blood Flow and Microvascular Resistance Case Report.
  • The article, authored by Francesco Giannini, M.D., Maria Cecilia Hospital, Cotignola, Italy, describes objective improvements in the amount of oxygenated blood delivered to the heart muscle in two patients suffering from refractory angina treated with the Neovasc Reducer (Reducer).
  • The second patient was a 78-year-old male suffering from a blocked stented vessel and recurrent chest pain.
  • Neovasc is a specialty medical device company that develops, manufactures, and markets products for the rapidly growing cardiovascular marketplace.